Phase 1 Study to Evaluate Safety and Antiviral Activity of PBGENE-HBV in Adult Patients With Chronic Hepatitis B
← catalyst calendarNCT06680232 · readout ≤ 134 d
Sponsored by Precision BioSciences, Inc. (industry) · DTIL — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
45estimated
Sites
7
Countries
France, Hong Kong, Moldova +3
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-11-14 | actual | When the study began enrolling |
| Primary completion | Dec 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jun 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2024-11-08 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-14 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- HEPATITIS B CHRONIC
Intervention
- Biological: PBGENE-HBV
Primary outcome
what the primary-completion date above is the date OFSafety to Assess Treatment-emergent Adverse Events (TEAEs)
measured 4 weeks after final dose
Permalink · DTIL's whole pipeline · Catalyst calendar · Every registered study · What changed